Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Isotretinoin in Advanced Renal Cell Carcinoma
NCT00324740Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Feb 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat, isotretinoin in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Mar 2006; status: terminated.
02
Drugs
vorinostatisotretinoin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00324740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324740.